`
`
`
`
`
`Paper No.______
`Filed: June 25, 2015
`
`
`
`
`Filed on behalf of: AstraZeneca AB
`By:
`
`
`
`
`
`Charles E. Lipsey
`Finnegan, Henderson, Farabow,
` Garrett & Dunner, L.L.P.
`11955 Freedom Drive
`Reston, VA 20190
`Tel: 571-203-2700
`Fax: 202-208-4400
`Email: charles.lipsey@finnegan.com
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`___________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`___________________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner
`
`___________________________________
`
`Case IPR2015-01340
`Patent No. RE44,186
`
`___________________________________
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. §42.8(a)(2)
`
`
`
`
`
`
`
`
`
`
`
`
`In accordance with 37 C.F.R. §42.8(a)(2), Patent Owner AstraZeneca AB
`
`Case IPR2015-01340 for
`U.S. Patent No. RE44,186
`
`submits the following mandatory notices regarding the Petition for Inter Partes
`
`Review of U.S. Patent No. RE44,186 (“the ‘186 patent”). This notice is being
`
`timely filed within 21 days (June 25, 2015) of service of the petition (June 4,
`
`2015).
`
`Real parties-in-interest (§42.8(b)(1)): AstraZeneca AB is the Patent Owner and
`
`the real party-in-interest.
`
`Related Matters (§42.8(b)(2)): The ‘186 patent is at issue in AstraZeneca AB v.
`
`Mylan Pharmaceuticals Inc., 14-cv-00696 (D. Del. 2014); AstraZeneca AB v.
`
`Mylan Pharmaceuticals Inc., 14-cv-00094 (D.W. Va. 2014); AstraZeneca AB v.
`
`Aurobindo Pharma Ltd. et al., 14-cv-01469 and 14-cv-00664 (D. Del 2014);
`
`AstraZeneca AB v. Watson Laboratories, Inc., 14-cv-00666 (D. Del. 2014);
`
`AstraZeneca AB v. Actavis Laboratories FL, Inc., 14-cv-01356 (D. Del. 2014);
`
`AstraZeneca AB v. Sun Pharma Global FZE et al., 14-cv-00694 (D. Del. 2014);
`
`AstraZeneca AB v. Amneal Pharmaceuticals LLC., 14-cv-00697 (D. Del. 2014);
`
`and AstraZeneca AB v. Wockhardt Bio AG et al., 14-cv-00696 (D. Del. 2014).
`
`
`
`
`
`
`
`
`
`
`
`
`Lead and Back-Up Counsel (§42.8(b)(4))
`
`Case IPR2015-01340 for
`U.S. Patent No. RE44,186
`
`Lead Counsel for AstraZeneca AB is:
`
`Charles E. Lipsey, Reg. No. 28,165
`charles.lipsey@finnegan.com
`Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
`11955 Freedom Drive
`Reston, VA 20190
`Tel: 571-203-2700
`Fax: 202-208-4400
`
`
`Back-Up Counsel for AstraZeneca AB is:
`
`Eric E. Grondahl, Reg. No. 46,741
`egrondahl@mccarter.com
`McCarter & English LLP
`CityPlace I
`185 Asylum St.
`Hartford, CT 06103
`Tel: 860-275-6704
`Fax: 860-724-3397
`
`M. David Weingarten, Reg. No. 54,533
`david.weingarten@finnegan.com
`Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
`3500 SunTrust Plaza
`303 Peachtree Street, N.E.
`Atlanta, GA 30308
`Tel: 404-653-6400
`Fax: 404-653-6444
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-01340 for
`U.S. Patent No. RE44,186
`
`Service Information (§42.8(b)(4)) Please address all correspondence to the lead
`
`and backup counsel as shown above. Patent Owner consents to electronic service
`
`by e-mail at the e-mail addresses provided above.
`
`
`
`Dated: June 25, 2015
`
`
`
`
`
`Respectfully submitted,
`
`
`
` By: /M. David Weingarten/
`M. David Weingarten, Back-up Counsel
`Reg. No. 54,533
`Finnegan, Henderson, Farabow,
` Garrett & Dunner, L.L.P.
`3500 SunTrust Plaza
`303 Peachtree Street, N.E.
`Atlanta, GA 30308
`Tel: 404-653-6400
`
`Counsel for Patent Owner
`
`
`
`
`
`
`
`
`Case IPR2015-01340 for
`U.S. Patent No. RE44,186
`
`CERTIFICATE OF SERVICE
`
`Pursuant to §§42.6(e)(1), I certify that a true and correct copy of the
`
`foregoing Patent Owner’s Mandatory Notices Under 37 C.F.R. §42.8 was served
`by electronic mail on this 25 day of June, 2015 on Petitioner’s counsel of record as
`follows:
`
`Steven W. Parmelee
`Michael T. Rosato
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`sparmelee@wsgr.com
`mrosato@wsgr.com
`
`
`
`
`
`
`Dated: June 25, 2015
`
`
`
`
`
`
`
`
`
`
`
`/M. David Weingarten/
`M. David Weingarten, Back-up Counsel
`
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, L.L.P.
`
`